Liquidia Corp 8-K, filed Mar 14, 2022
Liquidia Corp (LQDA)
About this 8-K
Liquidia Corp filed this 8-K on March 14, 2022, reporting on events of March 11, 2022.
Items reported
- Item 8.01: Other events
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
| (Exact name of registrant as specified in its charter) | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) | |
Registrant’s telephone number, including
area code: (
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 8.01 | Other Events. |
On January 7, 2022, Liquidia Technologies, Inc. (the “Company”) filed a motion seeking summary judgment of invalidity of claims 1-3, 6, and 8-9 of U.S. Patent No. 9,593,066 (“the ’066 patent”) and claims 1-4, 6, and 8 of U.S. Patent No. 9,604,901 (“the ’901 patent”) due to collateral estoppel in the lawsuit filed by United Therapeutics Corporation (“United Therapeutics”) against the Company in the U.S. District Court for the District of Delaware (Case No. 1:20-cv-00755-RGA) (the “Hatch-Waxman Litigation”). On March 11, 2022, Magistrate Judge Jennifer L. Hall issued a recommendation to deny the Company’s motion on grounds that United Therapeutics did not have timely notice of the Company’s collateral estoppel argument and on grounds that the prior decision that served as the basis for collateral estoppel was decided based on a different standard of proof than the standard of proof that will apply in the Hatch-Waxman Litigation. In issuing her recommendation, Judge Hall expressly noted that she was not commenting on the validity of the asserted claims in the ‘066 or ‘901 patents or the likelihood that the Court may find the claims of the ‘066 and ‘901 patents invalid for the same reasons that the U.S. Patent Trial and Appeal Board found U.S. Patent No. 8,497,393 invalid. The parties have the opportunity to object to Judge Hall’s recommendation, after which Judge Richard G. Andrews, who is presiding over the Hatch-Waxman Litigation, will issue a decision on whether he adopts Judge Hall’s recommendation.
As previously disclosed, in December 2021, United Therapeutics agreed to the entry of judgment of the Company’s non-infringement of the ’901 patent based on the Court’s construction of certain terms in the patent. Accordingly, only the ‘066 patent and U.S. Patent No. 10,716,793 (‘793 patent) remain at issue in the Hatch-Waxman Litigation. Trial is scheduled for March 28-30, 2022, with closing arguments to be held on March 31, 2022.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| March 14, 2022 | Liquidia Corporation | ||
| By: | /s/ Michael Kaseta | ||
| Name: | Michael Kaseta | ||